New Bill Would Perpetuate FDA-State Compounding Confusion
A bill aimed at revamping the regulation of compounded drugs is poised to sail through Congress, but attorneys say that by allowing manufacturers to decide whether they want to be overseen...To view the full article, register now.
Already a subscriber? Click here to view full article